THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS

Similar documents
Chapter 1. Introduction

A STUDY OF THE LEVELS OF GLUTATHIONE PEROXIDASE IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS

Midlife vascular risk factors and Alzheimer s disease in later life: longitudinal, population based study

Arterial Age and Shift Work

Long-term follow-up studies suggest that elevated blood

ORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease

Trajectories of different cognitive domains in community-dwelling older adults

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

Chapter 4. Cognitive decline precedes late-life longitudinal changes in vascular risk factors

Review Article Total Cholesterol and the Risk of Parkinson s Disease: A Review for Some New Findings

COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E

During the last 2 decades, evidence has accumulated that a high cholesterol level may

DECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE

UNIVERSITY OF WESTERN ONTARIO

Learning objectives 6/20/2018

Thesis for doctoral degree (Ph.D.) 2007 Predictors of cognitive decline in memory clinic patients. Christin Andersson. Christin Andersson

The distinction between vascular dementia and Alzheimer

Ph D THESIS ABSTRACT

Proportion of Dementia and its Associated Factors Among Elderly Patients Attending Outpatient Clinics of Universiti Sains Malaysia Hospital

Four Tissue Segmentation in ADNI II

ORIGINAL CONTRIBUTION. Functional Correlates and Prevalence of Mild Parkinsonian Signs in a Community Population of Older People

Cognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.

Fact Sheet Alzheimer s disease

Pulse wave velocity, augmentation index and arterial age in students

ORIGINAL CONTRIBUTION. History of Vascular Disease and Mild Parkinsonian Signs in Community-Dwelling Elderly Individuals

Development of the LIfestyle for BRAin Health (LIBRA) score. Sebastian Köhler, Kay Deckers, Martin van Boxtel, Frans Verhey

Mædica - a Journal of Clinical Medicine

Depression: An Important Risk Factor for Cognitive Decline

DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA

ORTHOSTATIC INTOLERANCE AN EXPRESSION OF AUTONOMIC DISFUNCTION IN PARKINSON S DISEASE

Mild Cognitive Impairment

김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과

Post Stroke Cognitive Decline

Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study.

Supplementary Online Content

Basal ganglia motor circuit

Hypertension and Neuropsychiatric Symptoms in Patients with Drug-Naïve Alzheimer s Disease

CRITICALLY APPRAISED PAPER (CAP)

Hyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine

Evaluation of Preventive Care Program for Cognitive Function Decline among Community-dwelling Frail Elderly People A Pilot Study

Dementia Care Pathway

NEUROPSYCHOMETRIC TESTS

ORIGINAL CONTRIBUTION. Risk Factors for Mild Cognitive Impairment. study the Cardiovascular Health Study Cognition Study.

Epidemiology Old Age

SUPPLEMENTARY APPENDIX

Central Pressures and Prehypertension

ORIGINAL INVESTIGATION. Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia

The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Heterogeneity in Risk Factors for Cognitive Impairment, No Dementia: Population- Based Longitudinal Study From the Kungsholmen Project

CHAPTER 2 CRITERION VALIDITY OF AN ATTENTION- DEFICIT/HYPERACTIVITY DISORDER (ADHD) SCREENING LIST FOR SCREENING ADHD IN OLDER ADULTS AGED YEARS

Cognitive Reserve and the Relationship Between Depressive Symptoms and Awareness of Deficits in Dementia

OXIDATIVE STRESS IN SCHIZOPHRENIA - FOCUSING ON THE MAIN MARKERS

Comparison of the Assessment of Orthostatic Hypotension Using Peripheral and Central Blood Pressure Measurements

Original Article Correlation between serum high-density lipoprotein level and senile dementia risk: a meta analysis

Mini-review on the glucose metabolism modifications after pancreatic resection TIMOFTE Daniel 1 *, IONESCU Lidia 1, OCHIUZ Lacramioara 1

Lifestyle intervention to prevent cognitive impairment

EPIDEMIOLOGIC FACTORS, RISK FACTORS AND SCREENING ELEMENTS IN THE CERVICAL NEOPLASIA

Alzheimer s disease dementia: a neuropsychological approach

Mentis Cura November

02/04/2015. The structure of the talk. Dementia as a motor disorder. Movement, cognition & behaviour. Example 1. Example 2

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

WHOS complex needs clients data survey: assessment and treatment options

Platelet Amyloid Precursor Protein Processing: A Biomarker for Alzheimer s Disease.

Dementia. Assessing Brain Damage. Mental Status Examination

The Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL)

Overview of neurological changes in Alzheimer s disease. Eric Karran

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

SPECIAL ARTICLE. Risk Factors and Preventive Interventions for Alzheimer Disease

The Primary Care Guide To Understanding The Role Of The Metabolic Syndrome In Cognitive Decline Of Older Persons

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

Management of the Acutely Agitated Long Term Care Patient

The importance of cognitive ageing for understanding dementia

Ann Acad Med Singapore 2013;42:315-9 Key words: Cognitive impairment, Dementia, SPMSQ, Validation

Accelerated Memory Decline in Alzheimer s Disease With Apolipoprotein e4 Allele

EFFECTS OF A MULTICOMPONENT EXERCISE PROGRAMME ON PHYSICAL AND COGNITIVE FUNCTIONS OF INSTITUTIONALISED PATIENTS WITH ALZHEIMER S DISEASE

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

Dementia risk factors for Australian baby boomers

3 COMMON PSYCHIATRIC DISORDERS IN OLDER ADULTS: NEW INSIGHTS

Hallucinations, delusions, and cognitive decline in Alzheimer s disease

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

3/6/2019 DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING FINANCIAL DISCLOSURES LEARNING OBJECTIVES

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

International Forum on HIV and Rehabilitation Research

The Long-term Prognosis of Delirium

Evidence has indicated that elevated blood pressure, occurring

ORIGINAL INVESTIGATION. Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia

Nuplazid. Nuplazid (pimavanserin) Description

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Secrets of delaying aging and living disease free Part 1

Cognitive impairment is a common disorder in elderly

The effect of education and occupational complexity on rate of cognitive decline in Alzheimer s patients

Overview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?

DEMENTIA DUE TO ALZHEImer

Transcription:

Arch. Biol. Sci., Belgrade, 64 (2), 419-426, 2012 DOI:10.2298/ABS1202419J THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS CATALIN JOACABINE 1, MANUELA PADURARIU 1, A. CIOBICA 2, R. DOBRIN 1, C. D. POPESCU 1 and F. MITU 1 1 Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania 2 Alexandru Ioan Cuza University, Iasi 700506, Romania Abstract - Cardiovascular pathology appears to have a major impact in cognitive decline, and early identification and correction of cardiovascular morbidity could have a major protective impact on cognitive functioning. However, it is not clear how the risk factors for vascular disease can also be risk factors for a general cognitive decline. Regarding cholesterol, its implications in cognitive decline are not very well understood, considering that a high level of cholesterol has been associated with both an increased and decreased risk of dementia. In the present context, we decided to study correlations between cholesterol concentration and the various subdomains of some main psychometric tests, such as MMSE (Mini-Mental State Examination) and MoCA (The Montreal Cognitive Assessment), as well as some measurements for systemic arterial stiffness (brachial and aortic augmentation index) and how they correlate with the aforementioned psychometric parameters. Our results provide additional evidence for a correlation between cholesterol levels and cognitive subdomains (with special focus on orientation, attention, recent memory and long-term memory). Additionally, a significant correlation was found between the brachial and aortic augmentation index and the results of both MMSE and MOCA tests. Key words: Cholesterol, cognitive deficits, brachial and aortic augmentation index INTRODUCTION Cognitive deficits generally increase with aging. Also, the presence of vascular risk factors such as hypertension, cholesterol, diabetes mellitus or the presence of heart diseases may increase the risk of developing Alzheimer s disease (AD) (McCullagh et al., 2001, Schneider et al., 2004, Luchsinger et al., 2005, Ciobica et al., 2011c). In this way, cardiovascular pathology appears to have a major impact in cognitive decline, and an early identification and correction of cardiovascular morbidity could have a major protective impact on cognitive functioning (Ciobica et al., 2009, 2011a, b). However, it is not very clear how the risk factors for vascular disease can also be risk factors for a general cognitive decline. We previously studied the possible connections between blood pressure and body mass index to the cognitive functions in patients with cardiovascular risk factors (Joacabine et al., 2011a, b). It is also believed that hypertension and hypercholesterolemia increase the risk of dementia by inducing atherosclerosis and impairing blood flow, but they may also directly induce the neurodegeneration of Alzheimer s disease (Kivipelto et al., 2001). Regarding cholesterol, it is generally accepted that high total choles- 419

420 CATALIN JOACABINE ET AL. terol is a common marker of cardiovascular and cerebrovascular pathology. However, its implications in cognitive decline are not very well understood, considering that a high level of cholesterol has been associated with both an increased and decreased risk of dementia (Notkola et al., 1998, Kivipelto et al., 2002, Solomon et al., 2007, Ciobica et al., 2011). We decided to study the degree of cognitive decline in selected patients with reported cardiovascular problems. Moreover, in the present paper we will extensively present the correlations between cholesterol concentration and the various subdomains of some of the main psychometric tests, like MMSE (Mini-Mental State Examination) and MoCA (The Montreal Cognitive Assessment). Additionally, considering the importance of cholesterol in increasing vascular resistance and rigidity, in the present paper we will determine some indices for peripheral vascular resistance (brachial and aortic augmentation index, which are a measure for the systemic arterial stiffness (Fantin et al., 2007)) and how they correlate with the aforementioned psychometric parameters. MATERIALS AND METHODS This study (n=95 patients) consisted of 80 patients (46 females and 34 males; age: 61.2 years±4.7), with reported cardiovascular problems, and 15 healthy age-matched controls (9 females and 6 males; age: 59.5 years±5.8). Patients were recruited from the University Hospital of Psychiatry Socola, Iaşi, Romania. Exclusion criteria were represented by acute comorbidities, chronic unstable diseases as well as patients with other medical conditions that could lead to cognitive deficits apart from cardiovascular and metabolic dysfunction. Healthy control subjects had major psychiatric disorders excluded based on history taking and psychiatric examination, according to the DSM-IV checklist. The demographic data of the controls were chosen in order to match the patients with cardiovascular problems. Cognitive testing was performed in the morning, between 10-12 a. m. Blood samples were obtained in the morning before breakfast. Blood was allowed to clot and was centrifuged immediately (Padurariu et al., 2010 a, b). Sera were aliquoted into Eppendorf tubes and stored at -80 C until determination of serum total cholesterol concentrations, which was performed in the hospital central laboratory. The augmentation index is an indirect measure of arterial stiffness. It is calculated as augmentation pressure divided by pulse pressure 100 to give a percentage. With an increase in stiffness, there is a faster propagation of the forward pulse wave as well as a more rapid reflected wave (O Rourke et al., 2008). Measurement of the brachial and aortic augmentation index was performed by using a TensioMed Arteriograph (Budapest, Hungary). All readings recorded met the manufacturer s quality control standards integrated into the software package. The study was conducted according to provisions of the Helsinki Declaration and all the patients signed consent for participation in this study. Statistical analysis The results for the cholesterol levels and brachial and aortic augmentation index were analyzed using one-way analysis of variance (one-way ANOVA). All results are expressed as mean ± SEM. F values for which p<0.05 were regarded as statistically significant (Hritcu et al., 2011, Hogas et al., 2011, Padurariu et al., 2012). In addition, Pearson s correlation coefficient was used to evaluate the connection between the cholesterol levels or the brachial and aortic augmentation index values versus various subdomains of certain psychometric tests such as MMSE and MOCA. RESULTS Our initial analysis included cholesterol levels. As expected, we observed a significant increase (F(1.93)=19, p<0.001) in cholesterol concentration

THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC INDEX 421 in patients with reported cardiovascular problems, compared to our control group (Fig. 1). More importantly, when we analyzed the connections between the cholesterol levels and the results from the MMSE and MOCA tests, we found significant negative correlations for cholesterol vs. MMSE (n=95, r=-0.308, p= 0.002) (Fig. 2) and for cholesterol vs. MOCA (n=95, r=-0,366, p<0.0001) (Fig. 3). Additionally, we found significant negative correlations between the values of the cholesterol level and some of the subdomains of both MMSE: cholesterol vs. orientation (n=95, r=-0.195, p<0.047) (Fig. 4A), cholesterol vs. attention (n=95, r=-0.406, p< 0.0001) (Fig. 4C), cholesterol vs. recent memory (n=95, r=-0.305, p= 0.003) (Fig. 4D) and MOCA tests: cholesterol vs. long-term memory (n=95, r= -0.198, p= 0.048) (Fig. 5F). However, in the case of some subdomains of the MMSE test, we could not find any significant correlations as in the case of cholesterol vs. short-term memory (n=95, r=-0.094, p=0.364) (Fig. 4B), cholesterol vs. language (n=95, r=-0.094, p= 0.367) (Fig. 4E) and cholesterol vs. executive functions (n=95, r= -0.01, p=0.925) (Fig. 4F). Also, we did not observe any correlations between cholesterol values and the rest of the cognitive subdomains of the MOCA test: cholesterol vs. visuospatial/executive functions (n=95, r=-0.039, p= 0.711) (Fig. 5A), cholesterol vs. naming (n=95, r=-0.046, p=0.657) (Fig. 5B), cholesterol vs. attention (n=95, r=-0.156, p=0.132) (Fig. 5C), cholesterol vs. language (n=95, r=-0.105, p=0.315) (Fig. 5D), cholesterol vs. abstractization (n=95, r=-0.084, p=0.419) (Fig. 5E) and cholesterol vs. orientation (n=95, r=-0,077, p<0,456) (Fig. 5G). Regarding the values of the augmentation index, we demonstrated a significant decrease of both the brachial (F(1.93)=11, p=0.042) (Fig. 6), as well as aortic augmentation index (F(1.93)=19, p=0.03) (Fig. 7) in the patients with reported cardiovascular problems, as compared to the control group. Fig. 1. Cholesterol concentration in cardiovascular patients and controls. The values are mean ± S.E.M. (n=80 for cardiovascular patients and n=15 per control group). ** p < 0,001. Fig. 2. Correlations between cholesterol levels and MMSE (n=95, r= -0,308, p= 0,002) Fig. 3. Correlations between cholesterol levels and MOCA test. (n=95, r= -0,366, p< 0,0001).

422 CATALIN JOACABINE ET AL. Fig. 4. Correlations between cholesterol levels and the subdomains of MMSE.

THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC INDEX 423 Fig. 5. Correlations between cholesterol levels and the subdomains of MOCA test.

424 CATALIN JOACABINE ET AL. Fig. 6. Brachial augmentation index in cardiovascular patients and controls. The values are mean ± S.E.M. (n=80 for cardiovascular patients and n=15 per control group). * p = 0,042. Fig. 7. Aortic augmentation index in cardiovascular patients and controls. The values are mean ± S.E.M. (n=80 for cardiovascular patients and n=15 per control group). * p = 0,03. Fig. 8. Correlations between brachial/aortic augmentation index and the MMSE/MOCA tests.

THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC INDEX 425 More importantly, when we analyzed the connections between the cholesterol levels and the results from MMSE and MOCA tests, we found significant correlations between MMSE vs. brachial augmentation index (n=95, r=0.517, p<0.0001) (Fig. 8A), as well as for MMSE vs. aortic augmentation index (n=95, r= 0.591, p<0.0001) (Fig. 8B). Also, significant correlations were reported between MOCA vs. brachial augmentation index (n=95, r=0.493, p<0.0001) (Fig. 8C), as well as for MOCA vs. aortic augmentation index (n=95, r=0.589, p< 0.0001) (Fig. 8D). DISCUSSION Our results provide additional evidence for a correlation between cholesterol levels and cognitive deficits (Notkola et al., 1998, Kivipelto et al., 2002, Solomon et al., 2007, Ciobica et al., 2011), expressed in our study by the specific scores of the MMSE and MOCA tests. Moreover, we demonstrated a series of significant correlations between cholesterol values and some of the subdomains from the MMSE and MOCA tests. Additionally, a significant correlation was found between some measurements of the systemic arterial stiffness (brachial and aortic augmentation index) and the results of both MMSE and MOCA tests. As previously mentioned, a high level of cholesterol was associated with both an increased and decreased risk of dementia. It seems that this varies mainly with the age of the studied patients. In this way, a decreased level of serum cholesterol was demonstrated to have a positive correlation with cognitive regression in late-life (Solomon et al., 2007), while there is also evidence that cholesterol is starting to decrease several years before the onset of dementia, and this could be used as a marker for the risk of AD (Mielke et al., 2005). In addition, other studies identified cholesterol as a risk factor for AD when this was found in middle-aged patients (Notkola et al., 1998, Kivipelto et al., 2002, Solomon et al., 2007). Regarding the augmentation index, this is considered to be a measure of systemic arterial stiffness (Fantin et al., 2007, O Rourke et al., 2008). Previous studies have demonstrated an association between the augmentation index and risk factors of cardiovascular disease (Janner et al., 2011). In addition, there are many gaps in this area of research, especially regarding the age and gender differences of the observed associations (Janner et al., 2011). However, in our study we were more interested to find the connections between the brachial and aortic augmentation index and the results of some specific cognitive tests, such as MMSE and MOCA. The strong connections that were demonstrated between these aspects can be also applied at the central level and further studies in this area seem warranted. Interestingly enough, the brachial and aortic augmentation index exhibited much stronger connections with the cognitive tests, in comparison with cholesterol, which might suggest their possible superiority as markers for the cognitive decline. CONCLUSIONS The present study provides additional evidence for the existence of a correlation between cholesterol levels and cognitive deficits (with special focus on orientation, attention, recent memory and long-term memory). Moreover, we demonstrated significant connections between the measurements of systemic arterial stiffness, such as the brachial and aortic augmentation index, and the results of the specific cognitive tests (MMSE and MOCA). Acknowledgments - Ciobica Alin is supported by a POSDRU project /89/1.5/S/49944, Alexandru Ioan Cuza University, Iasi. The other authors declare that they have no potential conflicts of interest to disclose. REFERENCES Ciobica, A., Bild, V., Hritcu, L., Padurariu, M. and W. Bild (2011a). Effects of angiotensin II receptor antagonists on anxiety and some oxidative stress markers in rat. Central European Journal of Medicine 6, 331-340. Ciobica, A., Hritcu, L., Nastasa, V., Padurariu, M. and W. Bild (2011b). Inhibition of central angiotensin converting enzyme exerts anxiolytic effects by decreasing brain oxidative stress. J Med Biochem 30, 109 114. Ciobica, A., Padurariu, M., Bild, W. and C. Stefanescu (2011c). Cardiovascular risk factors as potential markers for mild

426 CATALIN JOACABINE ET AL. cognitive impairment and Alzheimer s disease. Psychiatr Danub 23, 333-340. Ciobica, A., Bild, W., Hritcu, L. and I. Haulica (2009). Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 109, 171-180. Fantin, F., Mattocks, A., Bulpitt, C.J., Banya, W. and C. Rajkumar (2007). Is augmentation index a good measure of vascular stiffness in the elderly? Age Ageing 36, 43-8. Hogas, M.., Ciobica, A., Hogas, S., Bild, V. and L. Hritcu (2011). The effects of two doses manganese administration on short-term spatial memory and anxiety-like behavior in rats. Arch. Biol. Sci., Belgrade 63, December 2011. Hritcu, L., M. Stefan, Costica Misaila, A. Ciobica, and G. Dumitru (2011). Effects of bacterial lipopolysaccharide exposure on immune responsiveness in a rodent model of Parkinson s disease. Arch. Biol. Sci., Belgrade 63, 99-105. Joacabine, C., Padurariu, M., Ciobica, A., Stefanescu, C. and C.D. Popescu (2011). The effects of systolic blood pressure on cognitive status: main focus on cognitive subdomains. Bulletin of Integrative Psychiatry 49, 11-16. Joacabine, C., Padurariu, M., Ciobica, A., Stefanescu, C., Lefter, R. and C.D. Popescu (2011). Some correlations between body mass index and cognitive status in patients with cardiovascular disorders. Analele stiintifice ale Universitatii Alexandru Ioan Cuza-Genetica si Biologie Moleculara 4, 23-29. Kivipelto, M., Helkala, E.L., Laakso, M.P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J. and A. Nissinen (2001). Midlife vascular risk factors and Alzheimer s disease in later life: longitudinal, population based study. BMJ 322, 1447-51. Luchsinger, J.A., Reitz, C., Honig, L.S., Tang, M.X., Shea, S. and R. Mayeux (2005). Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545 551. McCullagh, C.D., Craig, D., McIlroy, S.P. and A.P. Passmore (2001). Risk factors for dementia. Adv. Psychiatr. Treat 7, 24-31. Mielke, M.M., Zandi, P.P., Sjögren, M., Gustafson, D., Ostling, S. and B. Steen (2005). High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64, 1689-95. Notkola, I.L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J. and A. Nissinen (1998). Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer s disease. Neuroepidemiology 17, 14-20. O Rourke, M., Farnsworth, A. and J. O Rourke (2008). Aortic dimensions and stiffness in normal adults. JACC Cardiovasc Imaging 6, 749-51. Padurariu, M., Ciobica, A., Dobrin, I. and C. Stefanescu (2010a). Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479, 317-20. Padurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W. and C. Stefanescu (2010b). Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer s disease. Neurosci Lett 469, 6-10. Padurariu, M., Ciobica, A., Mavroudis, I., Fotiou, D. and S. Baloyannis (2012). Hippocampal neuronal loss in the CA 1 and CA3 areas of Alzheimer s disease patients. Arch. Biol. Sci., Belgrade. in press. Schneider, J.A., Wilson, R.S., Bienias, J.L., Evans, D.A. and D.A. Bennett (2004). Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 62, 1148 1155. Solomon, A., Kåreholt, I., Ngandu, T., Winblad, B., Nissinen, A. and J. Tuomilehto (2007). Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68, 751-6.